Harvard Apparatus Regenerative Technology Inc

Harvard Apparatus Regenerative Technology Inc has a highly leveraged capital structure, with a debt-to-equity ratio of 2.86 and a current ratio of 0.28, indicating significant liquidity constraints. The company reported negative operating and free cash flows of $960,000 and $2,024,000, respectively, and has no capital expenditures, suggesting a lack of reinvestment in growth. With total liabilities of $2.24 million and total equity of $175,000, the firm is highly leveraged and faces substantial financial risk. Profitability metrics are severely negative, with a return on equity of -11.6% and a return on assets of -0.84%, far below the industry median for biotechnology firms. The company reported a net loss of $2.03 million on revenue of $57 million, indicating poor cost control and operational efficiency. Gross profit of $45 million suggests some pricing power, but this is insufficient to offset operating expenses. The company operates in a single business segment focused on regenerative medicine and tissue engineering, with no geographic diversification disclosed in the financial data. Revenue concentration in a single product line and market exposes the company to significant demand and regulatory risks. Growth trajectory is negative, with no capital expenditures and a net loss in the latest reporting period. Analyst estimates for revenue are not available, and the company has not provided forward-looking guidance, suggesting uncertainty in its business model. Risk factors include high leverage, negative cash flows, and a lack of equity cushion, with a liquidity risk score of medium and a dilution risk score of low. The company has no dilution sources disclosed in recent filings, but its low equity base and high debt load suggest potential for future dilution if financing is required. Recent events include the absence of disclosed earnings calls or investor presentations, and no material regulatory or litigation updates in the latest filings. The company has not issued new shares or raised capital in the latest reporting period.